Separate terms with OR to return results that match either term.
 
Clear All
10,000 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
Show Entries
NDC-11 (Package) NDC-9 (Product) Generic Name Brand Name Strength SEER*Rx Category Major Class Minor Class Administration Route (Ascending) Package Effective Date Package Discontinuation Date Status
63323-0821-10 63323-0821 Bortezomib Bortezomib 3.5 mg/1 Chemotherapy Proteasome Inhibitor 26S Intravenous, Subcutaneous May 2, 2022 In Use
68001-0535-41 68001-0535 Pemetrexed Pemetrexed 100.0 mg/4mL Chemotherapy Antimetabolite Folic Acid Analog Intravenous July 4, 2022 In Use
68001-0536-41 68001-0536 Pemetrexed Pemetrexed 500.0 mg/20mL Chemotherapy Antimetabolite Folic Acid Analog Intravenous July 4, 2022 In Use
68001-0538-41 68001-0538 Pemetrexed disodium Pemetrexed 100.0 mg/4mL Chemotherapy Antimetabolite Folic Acid Analog Intravenous June 24, 2022 In Use
68001-0539-41 68001-0539 Pemetrexed disodium Pemetrexed 500.0 mg/20mL Chemotherapy Antimetabolite Folic Acid Analog Intravenous June 24, 2022 In Use
68001-0540-36 68001-0540 Bortezomib Bortezomib 3.5 mg/1 Chemotherapy Proteasome Inhibitor 26S Intravenous, Subcutaneous May 16, 2022 In Use
70121-1755-01 70121-1755 bevacizumab-maly ALYMSYS 400.0 mg/16mL Immunotherapy Monoclonal Antibody VEGF Intravenous April 15, 2022 In Use
70121-1755-07 70121-1755 bevacizumab-maly ALYMSYS 400.0 mg/16mL Immunotherapy Monoclonal Antibody VEGF Intravenous April 15, 2022 In Use
70121-1754-01 70121-1754 Bevacizumab-maly ALYMSYS 100.0 mg/4mL Immunotherapy Monoclonal Antibody VEGF Intravenous April 15, 2022 In Use
70121-1754-07 70121-1754 Bevacizumab-maly ALYMSYS 100.0 mg/4mL Immunotherapy Monoclonal Antibody VEGF Intravenous April 15, 2022 In Use
70121-1570-07 70121-1570 Filgrastim RELEUKO 480.0 ug/.8mL Ancillary Therapy Immunostimulant Granulocyte Colony-Stimulating Factor Intravenous, Subcutaneous Feb. 25, 2022 In Use
70121-1570-01 70121-1570 Filgrastim RELEUKO 480.0 ug/.8mL Ancillary Therapy Immunostimulant Granulocyte Colony-Stimulating Factor Intravenous, Subcutaneous Feb. 25, 2022 In Use
70710-1411-01 70710-1411 BORTEZOMIB BORTEZOMIB 1.0 mg/mL Chemotherapy Proteasome Inhibitor 26S Intravenous, Subcutaneous May 2, 2022 In Use
70710-1654-01 70710-1654 Pemetrexed disodium Pemetrexed 100.0 mg/4mL Chemotherapy Antimetabolite Folic Acid Analog Intravenous May 26, 2022 In Use
70710-1655-01 70710-1655 Pemetrexed disodium Pemetrexed 500.0 mg/20mL Chemotherapy Antimetabolite Folic Acid Analog Intravenous May 26, 2022 In Use
70710-1674-01 70710-1674 Pemetrexed disodium Pemetrexed 1000.0 mg/40mL Chemotherapy Antimetabolite Folic Acid Analog Intravenous May 26, 2022 In Use
70710-1839-01 70710-1839 Nelarabine Nelarabine 5.0 mg/mL Chemotherapy Antimetabolite Purine Analog Intravenous June 24, 2022 In Use
70710-1839-08 70710-1839 Nelarabine Nelarabine 5.0 mg/mL Chemotherapy Antimetabolite Purine Analog Intravenous June 24, 2022 In Use
70771-1691-01 70771-1691 Pemetrexed disodium Pemetrexed 100.0 mg/4mL Chemotherapy Antimetabolite Folic Acid Analog Intravenous May 26, 2022 In Use
70771-1692-01 70771-1692 Pemetrexed disodium Pemetrexed 500.0 mg/20mL Chemotherapy Antimetabolite Folic Acid Analog Intravenous May 26, 2022 In Use
70771-1693-01 70771-1693 Pemetrexed disodium Pemetrexed 1000.0 mg/40mL Chemotherapy Antimetabolite Folic Acid Analog Intravenous May 26, 2022 In Use
70771-1708-01 70771-1708 BORTEZOMIB BORTEZOMIB 1.0 mg/mL Chemotherapy Proteasome Inhibitor 26S Intravenous, Subcutaneous May 2, 2022 In Use
72611-0716-01 72611-0716 Dexrazoxane for Injection Dexrazoxane 500.0 mg/50mL Ancillary Therapy Chemoprotective Detoxifying Agent Intravenous Sept. 1, 2020 In Use
72611-0716-72 72611-0716 Dexrazoxane for Injection Dexrazoxane 500.0 mg/50mL Ancillary Therapy Chemoprotective Detoxifying Agent Intravenous June 1, 2022 In Use
00078-0683-06 00078-0683 Nelarabine Arranon 5.0 mg/mL Chemotherapy Antimetabolite Purine Analog Intravenous Oct. 5, 2016 In Use
00078-0683-61 00078-0683 Nelarabine Arranon 5.0 mg/mL Chemotherapy Antimetabolite Purine Analog Intravenous Aug. 2, 2019 In Use
00409-1062-01 00409-1062 Pemetrexed Pemetrexed 25.0 mg/mL Chemotherapy Antimetabolite Folic Acid Analog Intravenous June 20, 2022 In Use
45963-0613-53 45963-0613 Paclitaxel Paclitaxel 6.0 mg/mL Chemotherapy Antimitotic Agent Taxane Intravenous July 19, 2018 July 31, 2022 No Longer Used
45963-0613-56 45963-0613 Paclitaxel Paclitaxel 6.0 mg/mL Chemotherapy Antimitotic Agent Taxane Intravenous July 19, 2018 April 30, 2021 No Longer Used
45963-0613-59 45963-0613 Paclitaxel Paclitaxel 6.0 mg/mL Chemotherapy Antimitotic Agent Taxane Intravenous July 19, 2018 June 30, 2022 No Longer Used
45963-0613-83 45963-0613 Paclitaxel Paclitaxel 6.0 mg/mL Chemotherapy Antimitotic Agent Taxane Intravenous June 13, 2018 April 30, 2021 No Longer Used
45963-0613-86 45963-0613 Paclitaxel Paclitaxel 6.0 mg/mL Chemotherapy Antimitotic Agent Taxane Intravenous June 13, 2018 March 31, 2021 No Longer Used
45963-0613-89 45963-0613 Paclitaxel Paclitaxel 6.0 mg/mL Chemotherapy Antimitotic Agent Taxane Intravenous June 13, 2018 Aug. 31, 2021 No Longer Used
59572-0515-01 59572-0515 idecabtagene vicleucel Abecma 300000000.0 1/1 Immunotherapy CAR-T BCMA Intravenous March 26, 2021 In Use
59572-0515-02 59572-0515 idecabtagene vicleucel Abecma 300000000.0 1/1 Immunotherapy CAR-T BCMA Intravenous March 26, 2021 In Use
59572-0515-03 59572-0515 idecabtagene vicleucel Abecma 300000000.0 1/1 Immunotherapy CAR-T BCMA Intravenous March 26, 2021 In Use
59923-0701-00 59923-0701 Epirubicin Hydrochloride Epirubicin Hydrochloride 2.0 mg/mL Chemotherapy Antitumor Antibiotic Anthracycline Intravenous May 19, 2014 In Use
59923-0701-25 59923-0701 Epirubicin Hydrochloride Epirubicin Hydrochloride 2.0 mg/mL Chemotherapy Antitumor Antibiotic Anthracycline Intravenous May 19, 2014 In Use
73657-0020-01 73657-0020 melphalan flufenamide Pepaxto 20.0 mg/50mL, 20.0 mg/50mL Chemotherapy Alkylating Agent Nitrogen Mustard Intravenous Feb. 26, 2021 Aug. 13, 2022 No Longer Used
00143-9098-01 00143-9098 Bortezomib Bortezomib 3.5 mg/1 Chemotherapy Proteasome Inhibitor 26S Intravenous, Subcutaneous July 27, 2022 In Use
00143-9135-01 00143-9135 Mitomycin Mitomycin 20.0 mg/1 Chemotherapy Antitumor Antibiotic Alkylating Agent/ Mitomycin Intravenous Oct. 1, 2022 In Use
00338-0720-01 00338-0720 PEMETREXED PEMETREXED 100.0 mg/10mL Chemotherapy Antimetabolite Folic Acid Analog Intravenous Aug. 18, 2022 In Use
00409-1700-01 00409-1700 Bortezomib Bortezomib 3.5 mg/1 Chemotherapy Proteasome Inhibitor 26S Intravenous, Subcutaneous July 27, 2022 In Use
16729-0522-05 16729-0522 Pemetrexed disodium Pemetrexed 25.0 mg/mL Chemotherapy Antimetabolite Folic Acid Analog Intravenous Sept. 8, 2022 In Use
16729-0522-28 16729-0522 Pemetrexed disodium Pemetrexed 25.0 mg/mL Chemotherapy Antimetabolite Folic Acid Analog Intravenous Sept. 8, 2022 In Use
16729-0522-35 16729-0522 Pemetrexed disodium Pemetrexed 25.0 mg/mL Chemotherapy Antimetabolite Folic Acid Analog Intravenous Sept. 8, 2022 In Use
16729-0522-64 16729-0522 Pemetrexed disodium Pemetrexed 25.0 mg/mL Chemotherapy Antimetabolite Folic Acid Analog Intravenous Sept. 8, 2022 In Use
00781-3258-70 00781-3258 Bortezomib Bortezomib 3.5 mg/1 Chemotherapy Proteasome Inhibitor 26S Intravenous May 31, 2022 In Use
00143-9136-01 00143-9136 Mitomycin Mitomycin 40.0 mg/1 Chemotherapy Antitumor Antibiotic Alkylating Agent/ Mitomycin Intravenous Oct. 1, 2022 In Use
55150-0326-01 55150-0326 CLOFARABINE CLOFARABINE 1.0 mg/mL Chemotherapy Antimetabolite Purine Analog Intravenous Oct. 3, 2022 In Use

Found 10,000 results in 4 milliseconds — Export these results